Revelation Biosciences Advances Gemini for Chronic Kidney Disease with FDA IND Approval

Revelation Biosciences Advances Clinical Development of Gemini for Chronic Kidney Disease

Revelation Biosciences, Inc., a clinical-stage life sciences company specializing in trained immunity therapies, achieves a significant milestone with the U.S. Food and Drug Administration's acceptance of its investigational new drug (IND) application for Gemini. This approval enables the company to initiate a Phase 1b clinical study focused on assessing Gemini as a preconditioning treatment for patients suffering from chronic kidney disease (CKD). The multi-site trial will involve up to 40 participants across five cohorts, primarily evaluating the safety and tolerability of a single dose of Gemini. Secondary objectives include pharmacokinetics assessments and evaluating the drug's ability to modulate the innate immune response via various predictive biomarkers.

The Phase 1b study represents a critical step for Revelation, as successful results could lead to a Phase 2 trial aimed at reducing the incidence, duration, and severity of acute kidney injury (AKI) in patients undergoing coronary artery bypass graft (CABG) or cardiac valve surgery. According to CEO James Rolke, the company is committed to enhancing patient outcomes through the innovative properties of trained immunity, which Gemini aims to leverage. Rolke expresses pride in reaching this milestone, indicating a strong focus on advancing treatment options that can significantly impact the lives of patients with CKD and related conditions.

Gemini is an intravenously administered proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD®), which has shown promise in prior preclinical studies and initial Phase 1 trials. During these earlier studies, Gemini successfully met primary safety endpoints and revealed important pharmacodynamic activity through changes in biomarkers. Revelation Biosciences is positioning Gemini as part of a broader strategy to prevent or mitigate acute kidney injury, reduce post-surgical infections, and possibly slow the progression of chronic kidney disease, thereby addressing significant unmet medical needs in these areas.

In addition to the IND approval, the clinical study's design and objectives underscore the company's systematic approach to clinical development, emphasizing safety, tolerability, and the drug's immune-modulating potential. Revelation's commitment to innovating treatments through trained immunity aligns with its mission to improve health outcomes for patients at risk of serious kidney-related complications.

As the company prepares to embark on this clinical journey, it highlights the importance of ongoing research and development in addressing chronic diseases, particularly those linked to kidney function. The successful execution of the Phase 1b study could not only enhance the understanding of Gemini's therapeutic potential but also solidify Revelation Biosciences' position within the competitive landscape of life sciences dedicated to chronic disease management.